Literature DB >> 29391154

O-GlcNAcylation affects β-catenin and E-cadherin expression, cell motility and tumorigenicity of colorectal cancer.

Shani Ben Harosh-Davidovich1, Isam Khalaila2.   

Abstract

O-GlcNAcylation, the addition of β-N-acetylglucosamine (O-GlcNAc) moiety to Ser/Thr residues, is a sensor of the cell metabolic state. Cancer diseases such as colon, lung and breast cancer, possess deregulated O-GlcNAcylation. Studies during the last decade revealed that O-GlcNAcylation is implicated in cancer tumorigenesis and proliferation. The Wnt/β-catenin signaling pathway and cadherin-mediated adhesion are also implicated in epithelial-mesenchymal transition (EMT), a key cellular process in invasion and cancer metastasis. Often, deregulation of the Wnt pathway is caused by altered phosphorylation of its components. Specifically, phosphorylation of Ser or Thr residues of β-catenin affects its location and interaction with E-cadherin, thus facilitating cell-cell adhesion. Consistent with previous studies, the current study indicates that β-catenin is O-GlcNAcylated. To test the effect of O-GlcNAcylation on cell motility and how O-GlcNAcylation might affect β-catenin and E-cadherin functions, the enzyme machinery of O-GlcNAcylation was modulated either with chemical inhibitors or by gene silencing. When O-GlcNAcase (OGA) was inhibited, a global elevation of protein O-GlcNAcylation and increase in the expression of E-cadherin and β-catenin were noted. Concomitantly with enhanced O-GlcNAcylation, β-catenin transcriptional activity were elevated. Additionally, fibroblast cell motility was enhanced. Stable silenced cell lines with adenoviral OGA or adenoviral O-GlcNAc transferase (OGT) were established. Consistent with the results obtained by OGA chemical inhibition by TMG, OGT-silencing led to a significant reduction in β-catenin level. In vivo, murine orthotropic colorectal cancer model indicates that elevated O-GlcNAcylation leads to increased mortality rate, tumor and metastasis development. However, reduction in O-GlcNAcylation promoted survival that could be attributed to attenuated tumor and metastasis development. The results described herein provide circumstantial clues that O-GlcNAcylation deregulates β-catenin and E-cadherin expression and activity in fibroblast cell lines and this might influence EMT and cell motility, which may further influence tumor development and metastasis.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cancer metastasis; Cell-motility; E-cadherin; EMT; O-GlcNAcylation; β-catenin

Mesh:

Substances:

Year:  2018        PMID: 29391154     DOI: 10.1016/j.yexcr.2018.01.024

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  11 in total

1.  PGM3 regulates beta-catenin activity to promote colorectal cancer cell progression.

Authors:  Nan Zhang; Si Liu; Junxuan Xu; Tingting Ning; Sian Xie; Li Min; Shengquan Zhu; Shutian Zhang; Shengtao Zhu
Journal:  Exp Biol Med (Maywood)       Date:  2022-06-20

2.  Global profiling of O-GlcNAcylated and/or phosphorylated proteins in hepatoblastoma.

Authors:  Hang Song; Ji Ma; Zhixuan Bian; Shuhua Chen; Jiabei Zhu; Jing Wang; Nan Huang; Minzhi Yin; Fenyong Sun; Min Xu; Qiuhui Pan
Journal:  Signal Transduct Target Ther       Date:  2019-10-11

Review 3.  Hyperglycemia-Induced Aberrant Cell Proliferation; A Metabolic Challenge Mediated by Protein O-GlcNAc Modification.

Authors:  Tamás Nagy; Viktória Fisi; Dorottya Frank; Emese Kátai; Zsófia Nagy; Attila Miseta
Journal:  Cells       Date:  2019-08-28       Impact factor: 6.600

Review 4.  Research progress on O-GlcNAcylation in the occurrence, development, and treatment of colorectal cancer.

Authors:  Yao Liu; Fang-Xing Peng
Journal:  World J Gastrointest Surg       Date:  2021-02-27

5.  A living cell-based fluorescent reporter for high-throughput screening of anti-tumor drugs.

Authors:  Ningning Tang; Ling Li; Fei Xie; Ying Lu; Zifan Zuo; Hao Shan; Quan Zhang; Lianwen Zhang
Journal:  J Pharm Anal       Date:  2021-04-07

Review 6.  O-GlcNAcylation in Chronic Lymphocytic Leukemia and Other Blood Cancers.

Authors:  David E Spaner
Journal:  Front Immunol       Date:  2021-11-18       Impact factor: 7.561

Review 7.  O-GlcNAcylation: an important post-translational modification and a potential therapeutic target for cancer therapy.

Authors:  Qingsong Lu; Xiaozhen Zhang; Tingbo Liang; Xueli Bai
Journal:  Mol Med       Date:  2022-09-14       Impact factor: 6.376

Review 8.  Altered glycosylation in cancer: A promising target for biomarkers and therapeutics.

Authors:  Divya Thomas; Ashok Kumar Rathinavel; Prakash Radhakrishnan
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2020-11-04       Impact factor: 10.680

9.  GFAT1/HBP/O-GlcNAcylation Axis Regulates β-Catenin Activity to Promote Pancreatic Cancer Aggressiveness.

Authors:  Chunzeng Jia; Hengchao Li; Deliang Fu; Yu Lan
Journal:  Biomed Res Int       Date:  2020-02-15       Impact factor: 3.411

Review 10.  The Emerging Role of Galectins and O-GlcNAc Homeostasis in Processes of Cellular Differentiation.

Authors:  Rada Tazhitdinova; Alexander V Timoshenko
Journal:  Cells       Date:  2020-07-28       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.